Stockscreener 앱 받기
0.7071
14.14%
0.1097
전일 마감가:
$0.5974
열려 있는:
$0.5976
하루 거래량:
4.86M
Relative Volume:
65.34
시가총액:
$16.94M
수익:
-
순이익/손실:
$-7.33M
주가수익비율:
-1.9044
EPS:
-0.3713
순현금흐름:
$-8.02M
1주 성능:
+10.30%
1개월 성능:
-7.56%
6개월 성능:
-64.85%
1년 성능:
-84.40%
1일 변동 폭
$0.57
$0.9579
1주일 범위
$0.55
$0.9579
52주 변동 폭
$0.55
$10.00
Genenta Science Spa Adr Stock (GNTA) Company Profile
Compare GNTA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GNTA
Genenta Science Spa Adr
|
0.718 | 14.09M | 0 | -7.33M | -8.02M | -0.3713 |
VRTX
Vertex Pharmaceuticals Inc
|
439.91 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.21 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
824.57 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.98 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.25 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genenta Science Spa Adr Stock (GNTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-06-29 | 재개 | ROTH MKM | Buy |
| 2022-07-25 | 개시 | H.C. Wainwright | Buy |
| 2022-01-13 | 개시 | Maxim Group | Buy |
Genenta Science Spa Adr 주식(GNTA)의 최신 뉴스
GNTA Stock Price, Quote & Chart | GENENTA SCIENCE SPAADR (NASDAQ:GNTA) - ChartMill
Genenta Science Ends Ospedale San Raffaele License to Refocus Strategy - TipRanks
GNTA Stock Chart | GENENTA SCIENCE SPAADR (NASDAQ:GNTA) - ChartMill
Genenta Science to close US subsidiary and transition CFO to consulting role - Investing.com Canada
Genenta Science to close US subsidiary and transition CFO to consulting role By Investing.com - Investing.com South Africa
Genenta Science to Close U.S. Subsidiary and Shift CFO to Consulting Role - TipRanks
Genenta Science Moves Into Aerospace With Majority Investment Deal for Sòphia High Tech - The Globe and Mail
Genenta signs Definitive Agreements with Sophia High Tech - GlobeNewswire Inc.
Genenta Science Warned by Nasdaq Over Minimum Bid Price Compliance - The Globe and Mail
Genenta Science receives Nasdaq notice on minimum bid price compliance By Investing.com - Investing.com India
Genenta Science receives Nasdaq notice on minimum bid price compliance - Investing.com
What's going on in today's pre-market session - chartmill.com
Genenta Moves to Acquire Control of Italian Space-Defense Supplier Sòphia High Tech - TipRanks
Genenta Science Cancels Late-March Vote on Rebrand to Saentra Forge - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business - Finviz
11 Best Italian Stocks to Buy in 2026 - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Prenetics Group (PRE) - The Globe and Mail
Genenta Science Piv A Strategic Shift from Biotech to Defense - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail
Genenta Science stock soars on strategic pivot to defense sector By Investing.com - Investing.com Australia
Genenta Science stock soars on strategic pivot to defense sector - Investing.com
Genenta to Rebrand as Saentra Forge and Pivot into Italian National-Security Industrial Consolidator - TipRanks
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and BioLife Solutions (BLFS) - The Globe and Mail
Genenta Science (NASDAQ:GNTA) Trading Up 0.7% – Here’s What Happened - Defense World
Operating cash flow per share of Genenta Science SpA Sponsored ADR – FWB:K5F - TradingView — Track All Markets
Return on equity % of Genenta Science SpA Sponsored ADR – LSX:A3C9EK - TradingView
Healthy Upside Potential: Genenta Science SpA ADR (GNTA) - Setenews
Genenta Science stock soars after update on glioblastoma treatment study By Investing.com - Investing.com Australia
Genenta Science stock soars after update on glioblastoma treatment study - Investing.com
Genenta Science (NASDAQ:GNTA) Shares Down 3.4% – Should You Sell? - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Altimmune (ALT), Dogwood Therapeutics (DWTX) - The Globe and Mail
Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket - inkl
Genenta Science Secures $15 Million in Registered Direct Offering - TipRanks
Genenta Science Appoints New Board Member and Confirms CEO - TipRanks
These stocks are moving in today's pre-market session - ChartMill
Genenta Science Soars Following Strategic Collaboration with Anemocyte - StocksToTrade
Genenta Science Stock Skyrockets After Strategic Collaboration Announcement - StocksToTrade
Get insights into the top gainers and losers of Friday's after-hours session. - ChartMill
Leadership Change at Genenta Science SpA: Dr. Galimi Appointed Acting CMO - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS), AnaptysBio (ANAB) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Genenta Science S.p.A. Announces Shareholders’ Meeting for Strategic Amendments - TipRanks
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
Genenta Science Secures €20 Million Financing to Boost Cancer Therapy Development - TipRanks
Genenta Science announces amendment to pact with AGC Biologics - TipRanks
Genenta Science Spa Adr (GNTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
1.91%
자본화:
|
볼륨(24시간):